PPAR gamma Antibody 0 Publications

Mouse Monoclonal| Catalog number: 60127-1-Ig |CloneNo.: 4E12F10

  • Print page
  • Download PDF

-_-

Freight/Packing

Con: 150 μg/150 μl

Choose size:

Please visit your regions distributor:

Tested Applications

Applications:
ELISA
Application not tested? Please see our Guarantee




Species specificity:
human

Recommended dilution:

Product Information


Source:
Mouse

Purification method:
Caprylic acid/ammonium sulfate precipitation

Isotype:
IgG1

Storage:
PBS with 0.1% sodium azide and 50% glycerol pH 7.3. Store at -20oC. Aliquoting is unnecessary for -20oC storage.

Immunogen Information


Full name:
peroxisome proliferator-activated receptor gamma

Calculated molecular weight:
58 kDa

Observed molecular weight:
50-60 kDa

GenBank accession number:

Gene ID (NCBI):

Gene symbol
PPARG

Synonyms
Background

Peroxisome Proliferator-Activated Receptors (PPARs) are ligand-activated intracellular transcription factors, members of the nuclear hormone receptor superfamily (NR), that include estrogen, thyroid hormone receptors, retinoic acid, Vitamin D3 as well as retinoid X receptors (RXRs). The PPAR subfamily consists of three subtypes encoded by distinct genes denoted PPARα (NR1C1), PPARβ/δ (NR1C2) and PPARγ (NR1C3), which are activated by selective ligands. PPARγ, also named as PPARG, contains one nuclear receptor DNA-binding domain and is a receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. It plays an important role in the regulation of lipid homeostasis, adipogenesis, insulin resistance, and development of various organs. Defects in PPARG are the cause of familial partial lipodystrophy type 3 (FPLD3) and may be associated with susceptibility to obesity (OBESITY). Defects in PPARG can lead to type 2 insulin-resistant diabetes and hyptertension. PPARG mutations may be associated with colon cancer. Genetic variations in PPARG can be associated with susceptibility to glioma type 1 (GLM1). This antibody is a mouse monoclonal antibody raised against residues near the C terminus of human PPARG.


Back
to top